DOTmed December 5, 2023
Paying $400 million upfront, Johnson & Johnson MedTech has acquired and made cardiac manufacturer Laminar part of its subsidiary, Biosense Webster, which designs technology for diagnosing and treating cardiac arrhythmia.
Laminar has developed a solution for eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib), which makes them more than five times as likely to experience a stroke. LAA closure is FDA-approved to reduce the risk of thromboembolism in AFib patients who cannot tolerate long-term blood thinners.
Its approach uses rotational motion to eliminate the LAA rather than plugs to occlude it like current commercial catheter-based procedure devices, and the company recently received FDA approval to conduct a U.S. pivotal study, with enrollment to begin in...
Today's Sponsors
Today's Sponsor